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Abstract
There is a need for analytical methods capable of monitoring blood antibiotic levels in real time. Here we present a method for quantifying
antibiotic levels in whole blood that does not require any sample pretreatment. The tests employ the enzyme penicillinase to assay for
penicillin G, penicillin V and ampicillin using a ﬂow-injected biosensor, the Enzyme Thermistor. Optimal ﬂow rates, sample volumes and pH
were determined to be 0.5 mL/min, 100 lL and 7.0, respectively. Analysis of the antibiotics diluted in buffer gave a linear range of 0.17–
5.0 mM. Calibration curves prepared using blood spiked with the antibiotics gave a linear range of 0.17–2.0 mM. Linear regression values for
all of the calibration curves were 0.998 or higher. Assay cycle time was 5 min. The relative standard deviation value for 100 determinations
of a mock blood sample spiked with penicillin G was 6.71%. Despite the elimination of sample pretreatment, no detectable clogging or signal
drift was observed. The assay provides a fast, simple, reliable analytical method for determining antibiotic concentrations in blood without
the need for any sample pretreatment. This is an important ﬁrst step towards developing a device capable of real-time monitoring of
antibiotic levels in whole blood. The technology has the potential to signiﬁcantly improve the outcomes of patients undergoing critical care.
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Introduction
Antimicrobial resistance is rapidly becoming a major threat to
global public health. The World Health Organization estimates
that infectious and parasitic diseases are the second leading
cause of death worldwide [1]. Multi-drug resistance has major
economic consequences as well [2]. With few new antibiotics
in the ‘pipeline’, health authorities will have to make do with
the antibiotics that are currently available [3,4]. As a result,
there is a global drive to reduce the development and spread
of antibiotic resistance [5].
Unfortunately current diagnostic methods for identifying
diseases are slow, which results in over-prescription of
antibiotics, which increases the spread of antibiotic resistance
[6]. Faster diagnostics have been developed, but these
methods are expensive, which is delaying their implementation
[7,8]. Improved antibiotic testing regimens are urgently
needed. One approach is to continuously monitor antibiotic
blood levels. This has the potential to dramatically improve
patient outcomes, especially for patients undergoing critical
care treatment, such as trauma victims, patients with postop-
erative infections and those undergoing treatment of multire-
sistance. Current assay methodology is too slow for real-time
antibiotic monitoring.
In this context, enzyme-based biosensor assays have several
advantages [9]. First, enzyme speciﬁcity makes it possible to
speciﬁcally identify compounds, which eliminates the need for
time consuming analytical identiﬁcation. Second, over 200
different b-lactamases have been identiﬁed to date [10],
which provides a range of choices. Third, these enzymes are
robust, highly active enzymes making them ideal for thermal
biosensing [11]. Fourth, our assay detects primarily unbound,
biologically active antibiotics and so provides a more accurate
measurement of activity. In the case of antibiotics, bioavail-
ability is particularly important because serum proteins bind
antibiotics [12].
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Our group has developed a ﬂow-injected thermal enzyme
biosensor, the Enzyme Thermistor. This device detects the
heat generated by enzymatic reactions to quantify the pres-
ence of speciﬁc analytes [13,14]. To achieve real-time mon-
itoring, it was necessary to eliminate sample treatment.
Analysis of unpretreated blood is considered very difﬁcult.
As a result, few assays based on whole blood analysis have
been published despite growing interest from medical practi-
tioners. Here we present the development of a method that
employs penicillinase to detect b-lactam antibiotics in whole
unpretreated blood using the Enzyme Thermistor device.
Materials and Methods
Chemicals and materials
All chromatographic materials were purchased from Sigma (St
Louis, MO, USA). Imipenem was bought from Fresenius Kabi
(Uppsala, Sweden). Penicillinase (E.C. 3.5.2.6) from Bacillus
cereus and penicillin G potassium salt were purchased from
Sigma-Aldrich (St Louis, MO, USA). The penicillin V potassium
salt and ampicillin were obtained from Sigma-Aldrich. The
propylamino-derivatized controlled-pore glass beads (CPG),
with a diameter of 125–140 lm and pore size of 50 nm, were
obtained from Steinachglas (Steinach, Germany). All other
chemicals were purchased from Sigma-Aldrich.
Instrumentation and column preparation
The single-channel Enzyme Thermistor device used in this
study has been previously described [14]. The setup consists of
a peristaltic pump (Gilson Minipuls 2, Villiers-le-Bel, France)
mounted with one tube for each channel, a pneumatic injection
valve with a 100-lL sample loop (Valco Instrument Co. Inc.,
Houston, TX, USA) and the Enzyme Thermistor instrument
(Omik Bioscience AB, Lund, Sweden). A schematic of the
device is shown in Fig. 1. The working temperature was set to
25°C and the ampliﬁer was set to 200 ampliﬁcation scale.
The enzyme column was prepared by immobilizing 50 units
of penicillinase onto CPG as previously described [15]. In brief,
700 mg CPG were glutaraldehyde activated in phosphate
buffer at room temperature under reduced pressure for
30 min, and then at ambient pressure for an additional 30 min.
The CPG were extensively washed, after which penicillinase
(50 units) was added. The CPG were incubated for 2 h at
room temperature, and then at 4°C overnight under agitation.
Enzyme-bound CPG were washed and remaining sites were
blocked by the addition of 1 mL coupling buffer containing
0.2 M ethanolamine. After 2 h incubation, the CPG were
washed and then packed into a column.
Antibiotic determinations
Phosphate buffer (100 mM, pH 7.0) and a modiﬁed PBS
(137 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4, 52 mM NaF and 3.4 mM EDTA, pH 7.4) were the
only buffers used in these studies. All the solutions were
preparing using de-ionized (18 MΩ) water from a Milli-Q
system (Millipore, Bedford, MA, USA).
Antibiotic stock solutions were prepared for penicillin G,
penicillin V and ampicillin in phosphate buffer. Antibiotic
dilution series were prepared in buffer using the antibiotic
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FIG. 1. Schematic for the ﬂow-injected
Enzyme Thermistor instrument.
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stock solutions. The phosphate buffer was used as running
buffer.
Blood samples (5 mL/tube) were taken in EDTA-coated
tubes from the antecubital vein of a healthy volunteer and
stored on ice after collection. Mock antibiotic blood dilution
series were prepared using the antibiotic stock solutions. The
modiﬁed PBS buffer was used as the running buffer.
A sample volume of 100 lL and a ﬂow rate of 0.5 mL/min
were used unless otherwise stated. The calibration curve data
were statistically analysed to determine the standard deviation
values and relative standard deviation (RSD) values. The
difference between groups was analysed using one-way analysis
of variance, and in cases where there was signiﬁcance, a
Dennett test was applied. p values less than 0.05 were
considered signiﬁcant.
Results
Assay optimization
A series of experiments were performed to determine the
effect of sample volume and ﬂow rate on the sensitivity and
linear range of the assay using penicillin G as the substrate
(data not shown). The results showed that these parameters
affected both the linear range and sensitivity of the assay. The
results were highly reproducible under all conditions tested.
For the purposes of this study, a ﬂow rate of 0.5 mL/min and a
sample volume of 100 lL were chosen.
Studies were also performed to determine the effect pH
had on the assay (Fig. 2). Background values have been
subtracted from each of the curves to eliminate pH-dependent
thermal interference effects. The results show that penicillin-
ase activity was highest at pH 6.5, which conﬁrms previously
reported results [16]. Linear regression values of 0.999136,
0.99827 and 0.987737 were obtained for pH 6.5, 7.0 and 7.5,
respectively. A neutral pH of 7.0 was chosen for the buffer
calibration studies.
Antibiotic determinations
The ability of the assay to measure penicillin G, penicillin V and
ampicillin in buffer and whole blood was investigated. The
breakdown of the b-lactam antibiotics by penicillinase resulted
in large, highly reproducible thermal signals. The linear range for
all of the antibiotics diluted in buffer was 0.17–3 mM. The linear
regression values were 0.999 or better in all cases (Fig. 3a).
Whole human blood samples were spiked with the
concentrated antibiotic solutions prepared in the modiﬁed
PBS buffer (see Materials and Methods section). These dilution
series were used to prepare calibration curves (Fig. 3b). Apart
from the addition of antibiotic, the blood samples were
untreated. The linear regression values for the curves were
0.9991 or better for all three antibiotics. The linear range and
slope of the resulting calibration curves was similar to those
obtained in the buffer study. However, the calibration curves
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FIG. 2. Penicillin G calibration curves at various buffer pH values.
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FIG. 3. Calibration curves for the antibiotics determined in buffer (a)
and in whole blood (b).
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for whole blood were slightly shifted downwards. Analysis of
whole blood alone gave a response of 37 mV, which was lower
than that obtained for buffer alone. To further investigate the
reason for this reduction in signal, penicillin G spiked buffer,
serum and whole blood dilution series were prepared and
analysed (Fig. 4). The linear regression values for these curves
were 0.999, 0.994 and 0.999 for buffer, serum and whole
blood, respectively.
Repeatability studies were performed at several different
penicillin G concentrations. The RSD values for buffer samples
spiked with 0.17, 0.34, 0.68 and 1.36 mM penicillin G were
6.60, 4.99, 4.32 and 3.46%, respectively. Typical chart recorder
data from analysis of penicillin G in buffer is shown in Fig. 5a.
Repeatability studies using whole blood spiked with 0.68 mM
penicillin G were also carried out (Fig. 5b). The RSD value for
100 determinations was 6.71%. The recovery for the whole
blood study was 87.8% of that found in the buffer study. No
column clogging was observed during the 100 whole-blood
sample injections. During the course of these studies, the
reproducibility of the penicillinase columns was monitored
over a period of several weeks. The calibration curves using 6-
week-old enzyme columns that had been used for more than
500 determinations had the same linear range and reproduc-
ibility as the original calibration curves (data not show).
Discussion
The choice of buffer pH was inﬂuenced by three factors:
enzymatic activity, buffering capacity and blood pH variation.
Penicillinase shows an activity optimum at pH 6.5 [16]. The
average pH value of blood is 7.4. An intermediate pH of 7.0
was chosen because phosphate buffer has optimal buffering
capacity at this pH and the enzyme shows good activity
(Fig. 2). Buffering capacity is especially important when making
blood measurements because blood pH can vary between pH
6.5 and 8.0 depending on the illness.
The calibration curves for penicillin G, penicillin V and
ampicillin were highly reproducible. As would be expected, the
thermal signal from penicillin G was slightly higher than for
penicillin V and ampicillin, because penicillin G is the true
substrate of penicillinase [16]. The spiked whole blood samples
were prepared using concentrated antibiotic solutions to
minimize dilution effects. Initially, the assay results were highly
variable. This was subsequently determined to be the result of
clogging caused by blood coagulation after storage (despite the
use of heparin-treated collection tubes) as well as of residual
metabolic activity. Addition of NaF and EDTA to the PBS buffer
eliminated these effects. The NaF inhibited residual metabolic
activity,which reduced the thermal noise signal (data not shown).
Addition of EDTA effectively inhibited coagulation, which
dramatically improved the buffer ﬂow uniformity. Combined,
these additions dramatically improved the repeatability of the
measurements. It is important to note that these additions were
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FIG. 5. Repeatability study using antibiotic-spiked whole human
blood: (a) actual chart recorder readout and (b) graph of the
0.68 mM penicillin G data set.
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only required when samples were stored before analysis and
would not be neededwhenmaking direct on-linemeasurements.
Interestingly, the blood calibration curves were shifted
upward compared with the buffer curves. Further analysis
revealed that whole blood injected alone gave rise to an
interference response signal of 37 mV. The magnitude of the
whole blood response corresponded to the upward shift seen
in the whole blood calibration curves. Furthermore, analysis of
serum showed a similar, but less pronounced shift. Our
hypothesis is that the thermal signal resulted from mixing of
the highly concentrated blood and serum samples with the
running buffer. The interference signal is highly reproducible
and therefore easily compensated for when making concen-
tration calculations. Apart from the calibration curve shift, the
linearity and sensitivity obtained from the buffer and whole
blood calibration curves were similar.
Antibiotic levels can be as high as 1 mM immediately after
injection, but fall rapidly within the ﬁrst hour as a result of
clearance by the kidneys. Typical blood concentrations are in the
0.2–0.5 mM range [17], which lies within the linear range of our
assay. Many factors inﬂuence clearance rates including the
degree of bacterial loading, type of antibiotic resistance, as well
as the general health status of the patient. Hence, the half-life of
antibiotics in blood varies considerably, which makes if difﬁcult
to maintain optimal antibiotic levels. Real-time antibiotic mon-
itoring in the 5–10 min range would make it possible to more
accurately treat critically ill patientswhere time is of the essence.
The repeatability for detecting penicillin G in whole blood
samples is adequate for clinical use, but if one considers the fact
that no sample pretreatment has been performed, the results
are exceptional. Nevertheless further improvement is needed.
Previous studies in our group have shown that the linear range
and speed of the assay can be extended by reducing the sample
volume [18]. Reducing sample volume would have the added
advantage of allowing faster pH equilibration of the blood
samples, which would further improve assay accuracy and
repeatability. No clogging was observed after injection of over
100 untreated whole blood samples. The system has exceptional
long-term stability, with minimal signal reduction after being
used to make more than 500 measurements over a 6-week
period. The linear range, repeatability and speed of the assay are
adequate for real-time monitoring of antibiotics in human blood.
Conclusions
Antimicrobial resistance to antibiotics is an ever increasing
global healthcare threat. Real-time antibiotic monitoring would
improve treatment and patient outcomes, as well as reducing
the spread of resistance. Current testing is too slow to meet
the demand of patients undergoing critical care, such as trauma
victims, patients with postoperative infections and those
receiving treatment of multiresistance. Here we present our
efforts to develop an assay and instrument for the real-time
monitoring of antibiotic levels in unpretreated whole human
blood. It is also important to note that the system required
minimum recalibration (once daily). To our knowledge, this is
the ﬁrst assay to be developed that is capable of measuring
antibiotics in whole blood without any sample pretreatment
whatsoever.
The sensitivity and repeatability of the assay are adequate
for use in clinical applications. The ability to sequentially inject
more than 100 unpretreated whole blood samples with highly
reproducible results (6.71% RSD) attests to the robustness of
the assay. No detectable clogging was observed. After 6 weeks
of use and over 500 injections, no signiﬁcant loss of sensitivity
or reproducibility was detected, which attests to the long-term
stability of system. The assay system fulﬁls the basic require-
ments needed to develop real-time monitoring of antibiotics in
blood. The system is convenient to operate, has a rapid
response time and adequate sensitivity for clinical use. The use
of reusable immobilized enzyme columns provides an eco-
nomical alternative to single test kits for point of care and
outpatient testing.
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